|
|
Karyotypic complexity of the NCI-60 drug-screening panel
Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ,
Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR
Cancer Res. 2003 Dec 15;63(24):8634-47
Abstract:
We used spectral karyotyping to provide a detailed analysis of karyotypic aberrations in the
diverse group of cancer cell lines established by the National Cancer Institute for the purpose of
anticancer drug discovery. Along with the karyotypic description of these cell lines we defined and
studied karyotypic complexity and heterogeneity (metaphase-to-metaphase variations) based on three
separate components of genomic anatomy: (a) ploidy; (b) numerical changes; and (c) structural
rearrangements. A wide variation in these parameters was evident in these cell lines, and different
association patterns between them were revealed. Analysis of the breakpoints and other specific
features of chromosomal changes across the entire set of cell lines or within particular lineages
pointed to a striking lability of centromeric regions that distinguishes the epithelial tumor cell
lines. We have also found that balanced translocations are as frequent in absolute number within the
cell lines derived from solid as from hematopoietic tumors. Important similarities were noticed
between karyotypic changes in cancer cell lines and that seen in primary tumors. This dataset offers
insights into the causes and consequences of the destabilizing events and chromosomal instability that
may occur during tumor development and progression. It also provides a foundation for investigating
associations between structural genome anatomy and cancer molecular markers and targets, gene
expression, gene dosage, and resistance or sensitivity to tens of thousands of molecular compounds.
Spectral Karyotyping (SKY) of the NCI 60 Cancer Cell Lines
|
